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Introduction
Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy, constituting a hematological emergency in the acute setting. Disseminated microvascular ischemia quickly culminates in multiorgan dysfunction and a high mortality rate without prompt management. The vast majority of TTP is caused by autoantibodies that bind to ADAMTS-13 and impair function [1] . Congenital TTP is caused by biallelic mutations present in the ADAMTS-13 gene, with two loss-of-function mutations required to fully inactivate the ADAMTS-13 gene product. Compound heterozygous mutations are most common (65%) and inherited from asymptomatic parents who each carry a different mutation. Individuals with homozygous mutations are more likely to have closely related parents [2] . Originally thought to be a disease of childhood, the diagnosis of congenital TTP is increasingly made in adulthood, especially in pregnancy [3, 4] . There is considerable variation in the age of onset, severity and frequency of acute episodes, reflecting genetic heterogeneity and susceptibility to precipitants such as surgery, pregnancy, infections, aging, hormonal changes and comorbidities.
Congenital TTP has been increasingly recognized over the last decade with improved diagnostic techniques. Treatment of congenital TTP is based on the use of plasma infusion (PI) or intermediate purity factor VIII concentrates, which contain ADAMTS-13. Both treatment modalities provide functional ADAMTS-13 levels, which promote the irreversible cleavage of the high-molecular-weight von Willebrand factor multimers (HMW VWF) [5] [6] [7] . In turn, both therapies have demonstrated efficacy in increasing the platelet count acutely and as prophylaxis in preventing relapse [9, 10] . However, there is little available evidence regarding the appropriate dosing requirements and interval between plasma infusions, with dose and dosing interval being selected empirically for each patient. Consequently, some patients are treated on demand because of circumstances such as pregnancy and infection, whereas others need regular infusions to prevent TTP [11] .
Studies of clearance mechanisms of VWF have demonstrated a half-life of 8-15 h, but with interindividual variation according to blood group, glycosylation and genetic mutations [12] . The behavior of ADAMTS-13 has been less explored. An early study demonstrated half-life activity of von Willebrand factor (VWF)-cleaving protease in two brothers with congenital TTP, suggesting a plasma half-life of 2-3 days [13] . A typical dosing interval of every 3 weeks would therefore appear too long, given such a half-life of ADAMTS-13, with a direct link between its levels and pharmacological activity.
In current practice, dosing and dose intervals of plasma therapy are guided by clinical symptoms, platelet count and lactate dehydrogenase levels. It is widely known that the systemic clearance of a drug determines its exposure at steady state. It also determines the elimination half-life in plasma and consequently informs the dosing rationale for therapies that show immediate pharmacodynamic effects [14] .
Objectives
We hypothesize that the individualization of treatment, both dose and dosing interval, can be guided by further evaluation of interindividual differences in the clearance of ADAMTS-13. Such an approach will allow for a more effective clinical management of the individual patient, which may not be predicted by empirically monitoring ADAMTS-13 levels. We therefore investigated the pharmacokinetics and interindividual variability in the elimination of ADAMTS-13 replacement using PI in six patients with confirmed congenital TTP.
Methods

Patients
Six congenital TTP cases on a regular PI regime were selected from a single institution. Congenital TTP was confirmed by the presence of microangiopathic hemolytic anemia and thrombocytopenia at presentation, ADAMTS-13 activity of less than 10%, no detectable anti-ADAMTS-13 IgG antibodies in both the acute phase and in remission after treatment, and confirmation by mutational analysis of the ADAMTS-13 gene [15] . Patients with previous history of end organ damage, such as stroke, or those who had a normal platelet count but were experiencing severe headaches, were treated with PI to improve their symptomatology. All patients were clinically well at the time of PK measurement, with no suggestion of active thrombotic microangiopathy as reflected by their full blood counts and biochemical markers such as lactate dehydrogenase (LDH). All consented to the study.
All patients received Octaplas LG, which contains mean levels of ADAMTS-13 of 104% and a mean VWF:RCo to VWF:Ag ratio of 0.55, which was consistent with a reduction in the number of HMW bands seen in the VWF multimer gels and is typical of this product [16] . Each patient was on an established dose regime and frequency of treatment was dictated by normalized platelet counts and LDH, ranging from 15.3 mL kg À1 weekly to 7.2 mL kg À1 every 3 weeks. Pharmacokinetic analysis was performed after a typical treatment dose and regimen for each patient.
Plasma samples
Citrated plasma samples were taken at baseline, before infusion of plasma, and 1 h and between 2 and 3 h postinfusion. Subsequent samples were taken daily for 7 days, with additional samples at days 10, 14 and 21 according to frequency of infusion.
VWF antigen/activity and factor VIII. VWF antigen/activity and factor VIII were analysed via Sysmex analysis, using Siemens kit (INNOVANCE Ò ; VWF Ac. Siemens Healthcare Diagnostics, Marburg, Germany) [17] . ADAMTS-13 activity. ADAMTS-13 activity was determined using an in-house FRETS-ADAMTS-13 activity assay (Fluorescence Resonance Energy Transfer) [18, 19] , with the normal range being 64-132 IU dL
À1
. ADAMTS-13 antigen. "ADAMTS13 antigen levels were determined using ELISA as previously described (Feys et 
Pharmacokinetic data analysis
A population pharmacokinetic model was used to characterize the pharmacokinetics of ADAMTS-13 following intravenous infusions. Model building criteria included: (i) successful minimization, (ii) standard error of estimates, (iii) termination of the covariance step, (iv) correlation between model parameters and (v) acceptable gradients at the last iteration. Fixed and random effects were introduced into the model in a stepwise manner. Interindividual variability in pharmacokinetic parameters was assumed to be log-normally distributed. Goodness of fit was assessed by graphical methods, including population and individual predicted vs. observed concentrations, conditional weighted residual vs. observed concentrations, and time. Comparison of hierarchical models was based on the likelihood ratio test [21] . Secondary pharmacokinetic parameters (area under the curve [AUC], C max and half-life) were then derived using non-compartmental principles. Modelling was performed using NON-MEM version 7.3 and PsN 4.6.0. Statistical and graphical summaries were implemented in R version 3.3.2.
Dose individualization. Using the individual pharmacokinetic parameters obtained for each patient, simulations were performed to explore the feasibility of optimizing dose and dosing regimens. Hypothetical target ADAMTS-13 activities of 10 and 50 IU dL À1 were set as references for the purpose of this analysis. Total plasma volume and dosing intervals were then estimated from the simulated scenarios.
Results
Six cases of congenital TTP were studied, five of which presented de novo in pregnancy and one in childhood.
The indications for regular plasma therapy were previous , whereas plasma infusion intervals range from 1 to 3 weeks. ADAMTS-13 activity was measured for each individual over time to allow pharmacokinetic modelling (Fig. 1) . The median incremental recovery (IR) was 0.023 IU mL À1 IU À1 kg À1 . To exclude the impact of VWF contained in PI on ADAMTS-13 levels and clearance, there was no significant increase in VWF activity from baseline, as measured throughout the time-points (Fig. 2) .
Pharmacokinetics of ADAMTS-13 ADAMTS-13 activity was best described by a two-compartment pharmacokinetic model with linear elimination. Interindividual variability was identified on clearance, central volume of distribution, intercompartmental clearance and the peripheral volume of distribution. The population clearance was found to be 25.41 mL h À1 (Table 2 ). All patients reached baseline ADAMTS-13 activity levels within 7-10 days of PI. ADAMTS-13 antigen showed a similar increase and subsequent decrease over the same period as ADAMTS-13 activity (Data S1). The median C max and AUC were 24.05 IU dL À1 and 31.5 IU*h À1 mL À1 , respectively (Table 3) . Given the interindividual differences in clearance, the half-life of ADAMTS-13 in these patients ranged from 82.6 to 189.5 h (3.4-7.9 days), with a median value of 130.3 h (Table 4) . 
Dose individualization
The attained levels of ADAMTS-13 in these patients were below circulating levels seen in non-TTP patients in the general population (Fig. 1) . The optimal target ADAMTS-13 activity level is not known. We simulated an individualized dose appropriate for each patient based on a hypothetical target for trough ADAMTS-13 activity of (i) 10 IU dL À1 (Fig. 3 ) and (ii) 50 IU dL À1 (Fig. 4) .
Simulations were performed for each patient to compare doses necessary to maintain this target trough level given their current dosing interval, or optimal dosing interval for each patient based on their current dose. For dose amount or plasma volume, our simulations show that an ADAMTS-13 level of 59.2-502 IU (mean 241.3) would be required to achieve a target ADAMTS-13 activity of 50 IU dL À1 , and this would be considerably reduced to 11.8-100.4 IU (mean 48.3) to achieve a trough ADAMTS-13 level of 10 IU dL À1 using plasma.
Similarly, our simulations show that plasma treatment every 1.5-3 days (mean 2.3) would be required to achieve target ADAMTS-13 activity of 50 IU dL À1 , but only every 4-10 days (mean 7.3) to achieve a trough ADAMTS-13 level of 10 IU dL À1 using plasma.
Discussion
This is the largest formal study investigating the pharmacokinetics of ADAMTS-13 in patients receiving PI for congenital TTP. The structural and functional relationship of ADAMTS-13 with ultra-large von Willebrand factor (VWF) has been well described, with consequent cleavage of VWF [22] . However, there is a paucity of data regarding the proteolysis, degradation and/or clearance of ADAMTS-13.
We have investigated the impact of PI on ADAMTS-13 activity, VWF and factor VIII in six females with congenital TTP. All but one was diagnosed after de novo episodes in pregnancy. Patients had a heterogeneous clinical picture, with therapy initiated for end organ damage, primarily stroke, or to prevent symptomatology, such as headaches/migraines, despite normal platelet and LDH levels.
Our data demonstrate an ADAMTS-13 elimination half-life of 82.6-189.5 h (3.4-7.9 days) following plasma therapy for congenital TTP. In addition, our data show that ADAMTS-13 clearance is not linked to higher VWF activity or antigen levels, as two patients with the highest VWF activity and antigen had low clearance and consequently long half-lives for ADAMTS-13 activity (144.6 and 149.4 h). Ultimately, it is the individual clearance of ADAMTS-13 that should guide dose and dosing interval. Such half-life and clearance data should clarify individual treatment rationale. All six patients demonstrate a remarkably similar trend of ADAMTS-13 antigen level in relation to ADAMTS-13 activity. This trend would be expected in congenital TTP, because there is no inhibitory activity causing interference as there would be in acquired TTP, and provides a useful confirmation of ADAMTS-13 activity. Our data support the close correlation of ADAMTS-13 activity and antigen as they peak after plasma infusion and degrade at a relatively constant rate despite variations in the impact of mutations in congenital TTP.
Furlan et al. published data regarding two brothers, both with a 'constitutional deficiency of von Willebrand factor-cleaving protease and no inhibitor' [13] . Following daily plasma exchange for 4 and 3 days respectively, the protease, or ADAMTS-13, was analyzed by VWF multimer assay, describing half-lives of 3.3 days and 2.1 days in each patient, respectively. Four further patients had half-life estimation following 3-5 mL kg À1 of plasma, and similar results were identified (i.e. a mean half-life of 2.8 days) [23] . Overall it was considered that such halflives were uniquely long for a proteolytic enzyme, because these are usually rapidly inactivated. Subsequent work has suggested that duration of the ADAMTS-13 effect is a result of firstly resistance of its VWF substrate to cleavage because of circulation in a closed conformation, [24, 25] and secondly the requirement for shear-induced unfolding of VWF for ADAMTS-13 to access the cleavage site [26] . It is also noted that multimeric assays are sensitive to low ADAMTS-13 activity levels but will be less accurate in the mid-normal range, with recognition of this being a cumbersome procedure requiring expertise [27] .
ADAMTS-13 is recognized as a plasma reprolysin-like metalloproteinase, primarily synthesized by the liver [26, 28] . Our estimated model parameters are in accordance with ADAMTS-13 as a plasma protein (i.e. its central volume of distribution at 3.61 L indicates that it is constrained to the plasma compartment). Clearance estimates (25.4 mL h À1 ) seem to reflect the range of values observed for other plasma proteins, including coagulation factors and immunoglobulin [29] [30] [31] [32] . We demonstrate a large interindividual variability in elimination half-life observed in the currently presented cohort (ranging between 82.6 and 189.5 h, or 3.4-7.9 days). This is clearly higher than that observed by Furlan et al. but it is difficult to extract meaning from direct comparison because of small patient numbers in both studies and different means of analysis.
Regulation of ADAMTS-13 in physiological conditions is poorly understood. Previous work has shown that VWF levels are not correlated with ADAMTS-13 activity in individuals who have normal VWF levels and probably normal multimer distributions. In VWF deficiency, however, such as type 3 von Willebrand disease, ADAMTS-13 levels may be up to 30% higher. In congenital TTP, it is more plausible that variability in ADAMTS-13 half-life is related to clearance mechanisms rather than plasma VWF concentrations. Clearance itself will reflect the ratio between elimination rate and ADAMTS-13 plasma concentration.
Our data show that the population clearance of ADAMTS-13 is 25.4 mL h À1 , resulting in a median halflife of 130 h (or 5.4 days). Shorter half-lives are therefore a consequence of faster rate of elimination from plasma, which in turn may be caused by differences in bodyweight and basal metabolism. Review of VWF levels in our cohort, whether activity or antigen, shows a less consistent pattern, matched by factor VIII. The most direct effect of ADAMTS-13 is on proteolysis of high-molecular-weight VWF, which we did not directly measure. Furthermore, the plasma used in these cases does not have significant HMW VWF multimers. ADAMTS-13 should not unduly affect the measured antigen and activity, as reflected by our results.
There were minimal changes in von Willebrand factor activity, either absolute or relative to baseline (Fig. 2) , suggesting that it is HMW VWF turnover that may determine duration of the ADAMTS-13 effect. This is consistent with Furlan's earlier data regarding both the purported half-life of ADAMTS-13 and the enduring effect related to being a plasma-bound protein [13] .
A recent phase I study has examined the PK profile of BAX-930, a recombinant ADAMTS-13 [33] . The study confirmed the safety and tolerability of the product during its first in-human use, with PK results suggesting comparable pharmacokinetic parameters to those seen following plasma infusions of the naturally occurring metalloprotein. Although a different method was used in the pharmacokinetic data analysis, our results are consistent with their findings for ADAMTS-13. By contrast, one should note that recombinant ADAMTS-13 has a clearance twice as high as that of naturally occurring ADAMTS-13. An immediate implication of such differences is that significantly higher doses of the recombinant ADAMTS-13 are required to attain the same levels observed at steady state with the natural moiety. Clearance values for the recombinant ADAMTS-13 ranged from 59.3 mL h À1 (after 40 U kg À1 dose) to 64.8 mL h
À1
(after 20 U kg À1 dose) vs. ADAMTS-13 systemic clearance of 16.5 to 37.7 mL h À1 observed in this study.
Despite the requirement for higher doses, this may not represent a limitation, given that recombinant ADAMTS-13 can achieve higher ADAMTS-13 peak levels than PI, for which the dose and dosing regimen is primarily restricted by the maximum allowable infusion volumes. The observed ADAMTS-13 half-life in our patient group was higher than expected based on previous PI data, and higher than that determined with recombinant ADAMTS-13.
Further work is necessary to define the optimal target ADAMTS-13 during the clinical management of TTP patients. We have used simulations to explore the feasibility of individualized protocols for each patient based on either dose or frequency of PI to target a plasma level of ADAMTS-13 of 10 IU dL À1 or 50 IU dL
, respectively. Targeting a hypothetical optimal ADAMTS-13 of > 10 IU dL À1 with either dose or interval (Fig. 3) to prevent symptoms potentially associated with TTP may be sufficient as well as clinically practical. Achieving a level of > 50 IU dL À1 represents a 'normal' level in the non-TTP population, but such a level was not witnessed in our cohort receiving PI, even at peak levels. The simulation models suggest that for either scheme it is not possible in clinical terms to achieve a level of 50 IU dL
: either the plasma volume required is too high or the frequency of PI would be too difficult to safely achieve the dose needed (Fig. 4) .
Future attempts to individualize and optimize therapy with either naturally occurring ADAMTS-13 in allogeneic plasma or recombinant ADAMTS-13, will need to consider whether clearance is indeed the best surrogate for the duration of effect of ADAMTS-13. If our therapeutic aim is to ensure the continued presence of ADAMTS-13, we firstly need to investigate whether we should treat more frequently than every 3-4 weeks, which has been derived from the historic estimate of the half-life of ADAMTS-13 of 2-3 days. A dose interval of less than five half-lives of ADAMTS-13 may be more clinically appropriate. Secondly, given the varied values in this current cohort of between 3.4 and 7.9 days, we should consider undertaking half-life analysis in patients, in order to maintain a higher ADAMTS-13 level between infusions, which would require more frequent dosing (e.g. every 1-2 weeks, as in some of these cases).
Limitations of our study include the small number of patients studied, performing PK analysis after one PI per patient (albeit in steady state) and rarity of the disease. It should also be noted that PK results are heterogeneous, with clear individual variation. With a larger study number, future work could include multivariate analysis of the various factors affecting the individual PK, such as age, weight, platelet count, VWF level, LDH and genetic mutations. The FRETS assay results are less sensitive at the lower end of range, which should be taken into account. There is also the possibility of ADAMTS-13-binding antibodies enhancing clearance, but not being detected in the anti-ADAMTS-13 IgG ELISA.
In optimizing the treatment of congenital TTP, further research is required to explore the individual determinants Fig. 3 . Individualized simulations of maintaining target trough ADAMTS-13 > 10 IU dL À1 with total dose amount (fixed frequency) or dosing interval (fixed dose amount). ADAMTS-13 dosing is determined by Octaplas content, and therefore volume of plasma. Octaplas ADAMTS-13 mean content is 1.13 IU mL À1 , AE 0.17. In practice, because ADAMTS-13 dosing is limited by the volume of plasma necessary to deliver ADAMTS-13, the frequency of PI is adapted accordingly. The figure shows each patient's simulation based on a target trough ADAMTS-13 level of > 10 IU dL
. Simulations were firstly based on dose amount (at fixed frequency), to continue at current dose frequency of weekly up to 3-weekly. Dosing ranged from 11.8 IU kg À1 weekly to 100.4 IU kg À1 every 2 weeks. Simulations were secondly based on dose frequency (at fixed dose), to continue at current dose amount. Treatment would be required every 4-10 days for our cohort with dose amount kept the same.
ADAMTS-13
Current regimen (IU kg -1 ) Optimised regimen (based on current dose) Activity over Time of catabolism and clearance. Moreover, there is a need to identify metrics for the long-term protective effects of ADAMTS-13. Without allowing overt disease relapse, judging the symptomatology of TTP can be subtle. Objective measures should indicate whether treatment is warranted and how we calculate the rationale for dose and frequency of prophylaxis requires further investigation. This is particularly pertinent and achievable in the upcoming era of recombinant ADAMTS-13 as an alternative to plasma infusion.
Addendum
A. Taylor performed research, analyzed data and wrote the paper. C. Vendramin performed research, analyzed data and reviewed the paper. S. Oosterholt analyzed data and reviewed the paper. O. Della Pasqua analyzed data and reviewed the paper. M. Scully designed the research and wrote and reviewed the paper. Fig. 4 . Individualized simulations of maintaining target trough ADAMTS-13 > 50 IU dL/L. As per Figure 3 , simulations were repeated for each individual, manipulating both dose and frequency of treatment. The target trough ADAMTS-13 level was 50 IU/dL rather than 10 IU/dL as in Figure 3 .
